Mainz Biomed Future Growth
Future criteria checks 2/6
Mainz Biomed's earnings are forecast to decline at 11.1% per annum while its annual revenue is expected to grow at 88.2% per year. EPS is expected to grow by 21.5% per annum.
Key information
-11.1%
Earnings growth rate
21.5%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 88.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 9 | -30 | N/A | N/A | 1 |
| 12/31/2025 | 2 | -30 | N/A | N/A | 1 |
| 12/31/2024 | 1 | -27 | N/A | N/A | 2 |
| 6/30/2024 | 1 | -23 | -20 | -19 | N/A |
| 3/31/2024 | 1 | -25 | -21 | -20 | N/A |
| 12/31/2023 | 1 | -26 | -24 | -22 | N/A |
| 9/30/2023 | 1 | -29 | -24 | -22 | N/A |
| 6/30/2023 | 1 | -29 | -21 | -19 | N/A |
| 3/31/2023 | 1 | -27 | -20 | -18 | N/A |
| 12/31/2022 | 1 | -26 | -15 | -15 | N/A |
| 9/30/2022 | 0 | -24 | -12 | -12 | N/A |
| 6/30/2022 | 0 | -24 | -10 | -10 | N/A |
| 3/31/2022 | 1 | -17 | -6 | -6 | N/A |
| 12/31/2021 | 1 | -12 | -3 | -3 | N/A |
| 12/31/2020 | 0 | -1 | 0 | 0 | N/A |
| 12/31/2019 | 0 | -1 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4TO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 4TO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 4TO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 4TO's revenue (88.2% per year) is forecast to grow faster than the German market (5.7% per year).
High Growth Revenue: 4TO's revenue (88.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 4TO's Return on Equity is forecast to be high in 3 years time